March 7, 2016 | By Varun Saxena
Johnson & Johnson ($JNJ) is hosting nanotechnology specialist NanoMedical Systems at its new JLABS life science incubator in Houston, signaling that it has interest in the company’s drug delivery implant and injectable antitumor particles.
The Austin, TX-based company makes the Personalized Molecular Drug-delivery System. The quarter-sized implant contains a chip from which the molecules diffuse into the body. According to the company website, the chip achieves “constant release” of the selected drug thanks to its so-called nanochannels, which are about the size of a specific drug molecule.
Meanwhile, NanoMedical Systems’ Multi-Stage nanoVector Drug Delivery System consists of a disc-shaped nanoporous silicon particle that transports drug payloads to cancerous tumors while protecting them from enzymatic degradation and the immune system.
And the company’s diagnostic chip can apparently separate “relatively large and abundant serum proteins and other matter that have little clinical significance from circulating peptides and protein fragments (possible biomarkers) that provide diagnostic potential.”